nctId: NCT06372457 id: CV027-1107 briefTitle: COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) acronym: COLLIGO-HCM overallStatus: ACTIVE_NOT_RECRUITING date: 2023-12-01 date: 2025-03-01 date: 2025-06-15 date: 2024-04-18 date: 2024-04-18 name: Bristol-Myers Squibb class: INDUSTRY briefSummary: COLLIGO-HCM is a global observational study that will conduct observational research of hypertrophic cardiomyopathy (HCM) treatment in real-world clinical practice. conditions: Hypertrophic Cardiomyopathy (HCM) studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 500 type: ESTIMATED name: Approved Hypertrophic Cardiomyopathy drug treatments name: Mavacamten measure: Participant age at Hypertrophic Cardiomyopathy (HCM) diagnosis measure: Participant age at mavacamten treatment initiation measure: Participant sex measure: Participant race/ethnicity measure: Participant insurance coverage measure: Participant employment status measure: Participant educational level measure: Date of Hypertrophic Cardiomyopathy (HCM) diagnosis measure: Participant body mass index (BMI) at Hypertrophic Cardiomyopathy (HCM) diagnosis measure: Hypertrophic Cardiomyopathy (HCM) subtype at diagnosis measure: Participant echocardiogram (ECHO) parameters at Hypertrophic Cardiomyopathy (HCM) diagnosis measure: Participant New York Heart Association (NYHA) class measure: Reason/trigger for initiating the path to Hypertrophic Cardiomyopathy (HCM) diagnosis measure: Date of reason/trigger that initiated the path to Hypertrophic Cardiomyopathy (HCM) diagnosis measure: Participant height measure: Participant weight measure: Participant blood pressure measure: Participant heart rate measure: Participant Hypertrophic Cardiomyopathy (HCM) symptoms measure: European participant CYP2C19 genotype measure: Participant family history of Hypertrophic Cardiomyopathy (HCM) measure: Participant family history of obstructive Hypertrophic Cardiomyopathy o(HCM) measure: Participant family history of sudden cardiac death (SCD) measure: Participant smoking status measure: Participant alcohol use measure: Participant recreational drug use measure: Participant involvement in a Hypertrophy Cardiomyopathy (HCM) randomized clinical trial (RCT) measure: Participant cardiovascular (CV) and CV-related comorbidities measure: Participant non-cardiovascular (CV)-related comorbidities measure: Participant electrocardiogram (ECG) rhythm results measure: Participant cardiac magnetic resonance imaging (MRI) results measure: Participant N-terminal pro-B-type natriuretic peptide (NT-proBNP) results measure: Participant cardiac troponin results measure: Participant cardiopulmonary exercise test (CPET) results measure: Participant cardiac monitoring results measure: Participant exercise test results measure: Participant blood creatine levels measure: Participant cardiovascular (CV) events measure: Type of procedures received by participants measure: Cardiovascular treatments prescribed to participants measure: Date of mavacamten prescription measure: Date of mavacamten treatment initiation measure: Date of mavacamten dosage change measure: Reason for mavacamten dosage change measure: Occurrence of mavacamten stable dose (a period of 6-months with the same dose) measure: Dates of follow-up after mavacamten treatment initiation measure: Date of mavacamten treatment interuption or discontinuation measure: Reason for mavacamten treatment interuption or discontinuation measure: Supportive care provided to participants measure: Heath care resource utilization (HCRU) measure: Hypertrophic Cardiomyopathy (HCM) symptom improvement post mavacamten treatment initiation measure: Participant obstructive Hypertrophic Cardiomyopathy (oHCM) symptoms measure: Participant family history of Hypertrophic Cardiomyopathy (HCM) or obstructive Hypertrophic Cardiomyopathy (oHCM) measure: Participant family history of sudden cardiac death (SCD) measure: Cardiovascular (CV) and CV-related comorbidities measure: Non-cardiovascular (non-CV) comorbidities measure: Participant electrocardiogram (ECG) rhythm results measure: Participant echocardiogram (ECHO) results measure: Participant cardiac MRI results measure: Participant NT-proBNP results measure: Participant cardiac tropin results measure: Participant cardiopulmonary exercise test (CPET) results measure: Participant cardiac monitoring results measure: Participant exercise test results measure: Hypertrophic Cardiomyopathy (HCM) subtype measure: Participant symptoms at Hypertrophic Cardiomyopathy (HCM) measure: Participant New York Heart Association (NYHA) class measure: Reason/trigger for initiating the path to Hypertrophic Cardiomyopathy (HCM) diagnosis measure: Date of reason/trigger that initiated the path to Hypertrophic Cardiomyopathy (HCM) diagnosis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IQVIA city: Durham state: North Carolina zip: 27703 country: United States lat: 35.99403 lon: -78.89862 hasResults: False